Working Groups (cont.)
Drug Development - To develop a mechanism to ensure that sponsors and FDA focus on pediatric use at the earliest appropriate stage in drug development. Working group was disbanded as this is addressed by the proposed rule.
Previous slide
Next slide
Back to first slide
View graphic version